Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.79 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.69 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.69 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.56 |
| ▸ | PDE1A | P54750 | 8/20 | 0.79 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.79 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.79 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.70 |
| ▸ | PDE6A | P16499 | 3/20 | 0.69 |
| ▸ | PDE2A | O00408 | 2/20 | 0.69 |
| ▸ | PDE6D | O43924 | 2/20 | 0.69 |
| ▸ | PDE9A | O76083 | 2/20 | 0.69 |
| ▸ | PDE6G | P18545 | 2/20 | 0.69 |
| ▸ | PDE4A | P27815 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | PDE6B | P35913 | 2/20 | 0.69 |
| ▸ | PDE6C | P51160 | 2/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823559 | 0.91 | PDE5A (0.94) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL5537 | 0.89 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE4B | |
| Hydrochloric Acid SCHEMBL974638 | 0.88 | PDE5A (0.98) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL24430082 | 0.87 | PDE5A (0.88) | PDE5APDE1APDE1BPDE1CPDE4B | |
| Lactic Acid SCHEMBL974011 | 0.87 | PDE5A (0.87) | PDE5APDE1APDE1BPDE1CPDE4B | |
| Citric Acid SCHEMBL14836744 | 0.85 | PDE5A (0.95) | PDE5APDE1APDE1BPDE1CPDE4B | |
| Citric Acid SCHEMBL14836746 | 0.85 | PDE5A (0.95) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12922554 | 0.85 | PDE5A (0.86) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL15407982 | 0.84 | PDE5A (0.79) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12922553 | 0.84 | PDE5A (0.94) | PDE5APDE1APDE1BPDE1CPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221825-B2 | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | Zhejiang Date Pharmaceutical Group Co. Ltd (CN) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | PDE3A, PDE3B, PDE5A | PDE5A 3/4885ADORA1 679/4885ADORA3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.